linjc16/ctgov huggingface dataset:
Epidemiological Study on the Vaccination Coverage of the Population Aged 75 Years and Over in Picardy. According to the Study of 200 Patients Followed by General Practitioners of the Somme in 2016.

Study Overview
=================
Brief Summary
-----------------
In France, the vaccination coverage of seniors is clearly deficient. It seems to be a cultural specificity, dating back more than 100 years, and which does not exist in Scandinavia, nor in much of the Anglo-Saxon world. Only influenza vaccination is a success for seniors. The high public health council sets the objective of immunization coverage in patients over 65 years of age to 80% whether or not the patient is benefiting from an exonerative ALD. The data collections carried out with the various pension funds objective have a lower immunization coverage with a rate ranging from 48.8 to 64%. Thus any medical consultation should be an opportunity to update the vaccination schedule of adults and the elderly.

Official Title
-----------------
Epidemiological Study on the Vaccination Coverage of the Population Aged 75 Years and Over in Picardy. According to the Study of 200 Patients Followed by General Practitioners of the Somme in 2016.

Conditions
-----------------
Vaccination, Elderly

Intervention / Treatment
-----------------
* Other: Analysis records of patients over 75 years of age


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Man or woman,> 75 years old. Seen in consultation at the doctor's office In 2016. Exclusion Criteria: Patient seen during a home visit. Patient resident in EHPAD.

Ages Eligible for Study
-----------------
Minimum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Analysis records of patients over 75 years of age|Demonstrate the percentage of patients over 75 years of age attending general medicine in the Somme, with an up-to-date vaccination schedule, in view of the HAS 2016 recommendations, for the following vaccines: DTp, influenza, pneumococcus, shingles.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Analysis of the rate of patients over 75 years old followed in general medicine in the Somme, with an up-to-date immunization schedule | Analysis of the rate of patients over 75 years old followed in general medicine in the Somme, with an up-to-date immunization schedule | 5 months |
Frank Score and Coronary Artery Disease

Study Overview
=================
Brief Summary
-----------------
Patients with coronary artery disease (CAD) were enrolled. CAD was diagnosed by coronary angiography which also resulted Syntax score. Images of left and right ears were captured by a digital camera. Frank score of each patients was calculated based on characteristics and numbers of wrinkles of the earlobes. Statistic analysis were carried out to analyze the correlation between Frank Score and Syntax Score.

Official Title
-----------------
Frank Score and Its Guidance Significance of Making Treatment Strategy in Coronary Artery Disease

Conditions
-----------------
Coronary Artery Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis coronary artery disease by coronary angiography Exclusion Criteria: Diagnosis of malignant tumor Positive heart transplant history Positive CABG history Positive PCI history Pregnant and lactating women Diagnosis of chronic kidney disease Any external ear trauma or disease history

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Syntax score completed | Syntax score is calculated by two experienced cardiologists according to the results of coronary angiography | Up to 30 minutes after completion of coronary angiography | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Follow-up MACE | MACE is reported in follow-up patients | When MACE is reported or up to 1 year after diagnosis of coronary artery disease | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Syntax score, Frank sign, Coronary angiography
Trial of a Culturally-Appropriate Weight Loss Intervention for Overweight Latino Children

Study Overview
=================
Brief Summary
-----------------
This project aims to conduct a unique, community-based intervention consisting of a randomized trial of a culturally-appropriate weight loss intervention for overweight Latino children in Milwaukee. The intervention promotes lifestyle changes through a low weight loss regimen, one or more physical activities ranging from soccer to hip-hop dance, and dietary counseling including cooking classes for parents. In addition to weight reduction for overweight Latino children, the project has the potential to reduce missed school days and improve self-esteem and quality of life.

Official Title
-----------------
A Randomized Controlled Trial of a Culturally-Appropriate Weight Loss Intervention for Overweight Latino Children

Conditions
-----------------
Overweight

Intervention / Treatment
-----------------
* Behavioral: Comprehensive weight management


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children must be of Latino descent At risk for becoming overweight or is overweight 6-17 years old. Exclusion Criteria: Age > 17 years old Not overweight or at risk for becoming overweight Non-Latino ethnicity/race.

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Comprehensive weight management|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in body mass index (BMI) z-score |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| height, weight, and BMI |  |  | 
| percent body fat |  |  | 
| physical activity |  |  | 
| sedentary activity |  |  | 
| dietary habits |  |  | 
| the child's quality of life |  |  | 
| self-esteem |  |  | 
| physical fitness |  |  | 
| selected health and use of health services measures (missed school days, parental missed work days, and number of healthcare provider visits for illness by child) |  |  | 
| the parents' BMI |  |  | 
| the child's satisfaction with opportunities to lose weight and increase physical activity in the past year |  |  | 
| the parents' satisfaction with opportunities for the child to lose weight and increase physical activity in the past year |  |  | 
| costs |  |  |
Changes in the Microbiome Associated With Transplantation

Study Overview
=================
Brief Summary
-----------------
To study the effects of organ transplantation and immunosuppression on the human microbiome, and to understand the interlinkage of changes in the microbiome with clinical events surrounding transplantation, and graft and patient clinical outcomes.

Detailed Description
-----------------
This study will involve the collection of oral swabs, saliva, urine and rectal swabs, blood and skin scrapings from patients before and after kidney and pancreas transplantation. At Day 0 and day 1, week 1, and at 3, 6, and 12 months. These samples will be collected longitudinally over a period of one year after transplantation and will be analysed using 16s rRNA gene sequencing in order to capture the dynamics of the microbiome after exposure to surgery, immunosuppression and the specific medication necessary during the process of transplantation. Two groups of recipients will be recruited, the first one includes kidney and/or pancreas transplant recipients from both deceased and living donors.

Official Title
-----------------
Changes in the Microbiome Associated With Transplantation

Conditions
-----------------
Microbiota

Intervention / Treatment
-----------------
* Other: Sample Collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Over 18 years of age. Under 75 years Participants must be able to receive and understand English verbal and written information regarding the study and give written, informed consent. Participants will be recipients of pancreas or kidney allografts Exclusion Criteria: Outside of stated age range. Unable to give informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Sample Collection|This study will involve the collection of oral swabs, saliva, urine and faeces samples, blood and skin scrapings from patients before and after kidney and pancreas transplantation at day 0, day 1, week 1 and at 3, 6 and 12 months post-transplant.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in the Microbiome following transplantation | The tissue samples will be examined to identify any microbial organisms. This process will involve cell identification and quantification using standard biological markers to identify cell types and numbers | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
microbiome
Feasibility Study Using the Xoft System for the Treatment of Endometrial Cancer

Study Overview
=================
Brief Summary
-----------------
Multicenter, non-randomized, feasibility study to evaluate the treatment and assess acute safety of the FDA Cleared Axxent Electronic Brachytherapy System and vaginal applicator for intracavitary vaginal cuff treatment according to the physician's current standard of care.

Official Title
-----------------
Feasibility Study Using the Xoft Axxent Electronic Brachytherapy System for the Treatment of Endometrial Cancer

Conditions
-----------------
Endometrial Cancer

Intervention / Treatment
-----------------
* Radiation: brachytherapy
* Radiation: Xoft Axxent Electronic Brachytherapy System


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Most types of endometrial (uterine) cancer Stage I and Stage II (see exclusion criteria below) Post hysterectomy Exclusion Criteria: Endometrial (uterine) cancer Stage IA Grade 1 Scleroderma Collagen vascular disease Active Lupus

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: endometrial cancer<br>Patients are treated with electronic brachytherapy for an FDA cleared indication. | Radiation: brachytherapy<br>* Electronic brachytherapy dose 21 Gy or 22 Gy in 3-4 fractions prescribed to 5mm depth, or electronic brachytherapy 16-18 Gy if EBRT is administered.<br>* Other names: Vaginal cuff;Radiation: Xoft Axxent Electronic Brachytherapy System<br>* 21-22 Gy in 3-4 fractions to 5mm or 16-18 Gy in 3 fractions prescribed to the surface.<br>* Other names: electronic;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess Number of Patients Who Were Able to Complete Treatment Delivery Using the Axxent Electronic Brachytherapy System |  | through completion of radiation therapy | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess Acute Safety Outcomes in Patients During and After Vaginal Cuff Brachytherapy Treatment With the Axxent Electronic Brachytherapy System as Incorporated in to the Physician's Current Standard of Practice |  | through 3 month post treatment | 
| Assess Occurence Rate of Toxicities |  | through 3 month follow up post treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
endometrial cancer, Uterine cancer, electronic brachytherapy, Xoft
Special Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to detect adverse drug reactions for long-term use (particularly clinically significant adverse drug reactions) occurring in clinical settings, to examine factors likely to affect the safety and efficacy in the Japanese asthma patients who are treated with fluticasone propionate/salmeterol xinafoate.

Official Title
-----------------
Special Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)

Conditions
-----------------
Respiratory Disorders

Intervention / Treatment
-----------------
* Drug: Salmeterol and Fluticasone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Must use fluticasone and salmeterol for the first time Must use fluticasone and salmeterol for long-term Exclusion Criteria: Patients with hypersensitivity to salmeterol and fluticasone Patients with infection which salmeterol and fluticasone is not effective Patients with deep mycosis
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients prescribed fluticasone and salmeterol<br>Patients with asthma prescribed fluticasone and salmeterol for long-term use during study period | Drug: Salmeterol and Fluticasone<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The number of incidence of adverse events in Japanese asthma patients treated with fluticasone and salmeterol for long-term |  | 1 year |
Oocyte Survival After Vitrification in an Open or Closed Device With Closed Storage.

Study Overview
=================
Brief Summary
-----------------
The survival rate (and embryo quality) of donor oocytes with two commercially available devices.

Detailed Description
-----------------
Donor sibling oocytes will be vitrified with two commercially available devices. The first device is closed vitrification with closed storage and the second device is open vitrification with closed storage. Oocyte acceptors receive oocytes from both devices. With the increase in cooling rate generated by the open vitrification (second device), we expect to get an increase in survival rate of 10%. Besides this, embryo quality will be assessed with oocytes obtained from both devices.

Official Title
-----------------
Oocyte Survival After Vitrification in an Open or Closed Commercial Device: Study on Sibling Donor Oocytes.

Conditions
-----------------
Survival, Embryo Quality

Intervention / Treatment
-----------------
* Device: CBSvit HS device
* Device: Cryotop SC device


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Donor: ≤36 years old on day of oocyte retrieval Donor: ≥ 6 mature oocytes Exclusion Criteria: Donor: < 6 mature oocytes

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 36 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: closed vitrification with closed storage<br>Half of the oocytes of every donor will be vitrified with the Cryo Bio Systems High Security vitrification (CBSvit HS) device; the standard device in our lab. | Device: CBSvit HS device<br>* closed vitrification with closed storage<br>|
| Experimental: open vitrification with closed storage<br>Half of the oocytes of every donor will be vitrified with the Cryotop closed system (Cryotop SC). | Device: Cryotop SC device<br>* open vitrification with closed storage<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Survival rate | The purpose is to assess the survival rate of donor oocytes with the two vitrification devices. | up to 6 days after every warming cycle | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Embryo development | The purpose is to analyse the pre-implantation development of donor oocytes vitrified with two different devices. | up to 6 days after every warming cycle | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
vitrification, oocyte, donor, open, closed
Reading Performance With a Video Magnifier

Study Overview
=================
Brief Summary
-----------------
The most common goal for patients with vision loss who present for vision rehabilitation is to be able to read. The video magnifier (a device which combines a video camera and a screen to view the print being magnified) is the device which most often allows low-vision individuals to read successfully for extended periods of time. Previous studies on the outcomes of vision rehabilitation have not identified which components of the vision rehabilitation are effective. The hypothesis of this project is that providing a video camera magnifier, with basic training in operating the device, will allow patients to enhance both objective reading ability and subjective report of reading competence.

Detailed Description
-----------------
Patients will be given a video magnifier at initial consultation or at the end of vision rehabilitation

Official Title
-----------------
The Effect of Video Camera Magnifier Use on Reading

Conditions
-----------------
Macular Degeneration

Intervention / Treatment
-----------------
* Behavioral: Video camera magnifier


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Central field loss and decreased visual acuity in the better seeing eye (<20/40 & >20/400). New patient at MEEI Low Vision Rehabilitation Clinic Exclusion Criteria: Dementia (Mini-Mental State Examination) Clinical depression (Geriatric Depression Scale) Patients who previously received vision rehabilitation Patients who have previously owned a desktop video magnifier

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Video camera magnifier<br> | Behavioral: Video camera magnifier<br>* reading with video camera magnifier<br>* Other names: Optelec video magnifier;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in objective reading performance | The subject undergoes testing to determine the change in reading performance on an objective scale. | baseline and one month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in subjective reading performance | The subject is asked to describe subjectively how they feel their ability to read has either improved or decreased since using the reader. | baseline and one month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
AMD, vision rehabilitation, video camera magnifier, IVI, DASS
Psychosocial Outcomes in Families of COVID-19 ICU Patients

Study Overview
=================
Brief Summary
-----------------
During the first part of the SRAS-COV2 pandemic, families were not allowed to visit the patients in ICU. We know that families can develop Family-PICS after their relatives' ICU stay. The aim of the study is to study the psychosocial outcomes of families of patients who were admitted in ICU for COVID-19 during the pandemic. The second objective was to search for any differences in outcomes whether families benefited from video-conferences with the medical team and their relatives or not during the ICU stay.

Official Title
-----------------
Psychosocial Outcomes in Families of Patients Admitted in ICU for COVID-19 During the Pandemic in Belgium

Conditions
-----------------
Critical Illness, Family, Psychological Stress, Covid19

Intervention / Treatment
-----------------
* Diagnostic Test: HADS questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: the referent family member of any patient admitted in ICU for COVID-19 during the first part of the pandemic Exclusion Criteria: cognitive disorders not French-speaking refusal to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: HADS questionnaire|Patients will be asked to answer to 3 questionnaires about anxiety and depression, post-traumatic stress disorder and health-related quality of life|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| occurence of anxiety and depression | sub scores of HADS questionnaire >7 | one month after ICU discharge | 
| occurence of anxiety and depression | sub scores of HADS questionnaire >7 | three months after ICU discharge | 
| occurence of acute stress | IES-R score > 22 | one month after ICU discharge | 
| occurence of post-traumatic stress disorder | IES-R score > 36 | three months after ICU discharge | 
| quality of life | assessed using the EQ-5D questionnaire | one month after ICU discharge | 
| quality of life | assessed using the EQ-5D questionnaire | three months after ICU discharge |